Bajaj Healthcare Limited filed its Business Responsibility and Sustainability Report (BRSR) for FY26 on August 29, 2026. The standalone report covers operations across six national manufacturing sites and one office.

The company reported a turnover of ₹611.03 crore and a net worth of ₹533.00 crore. Export sales contributed approximately 31% of the total turnover, with products supplied to over 62 countries.

Environmental Metrics

Total energy consumption rose to 501,706 Giga Joules in FY26 from 433,699 Giga Joules in FY25. Renewable energy usage increased significantly, accounting for 3,562 Giga Joules compared to 2,001 Giga Joules in the prior year.

Water withdrawal decreased to 201,614 kilolitres from 246,655 kilolitres. Total waste generated nearly doubled to 3,794 metric tonnes, driven by a rise in hazardous waste to 3,767.55 metric tonnes from 1,963.03 metric tonnes.

What the Numbers Show

Hazardous waste generation accounted for approximately 99% of total waste generated in FY26, up from roughly 98.7% in FY25. This indicates a high concentration of process-related waste relative to plastic or other non-hazardous streams.

Governance and Employees

The workforce consists of 884 employees and 135 workers. Female representation stands at 9.95% among employees. The board includes three women directors (30%), while key managerial personnel include two women (33.33%).

Employee turnover rate for permanent staff surged to 33.39% in FY26, compared to 3.9% in FY25 and 21% in FY24. No fatalities or lost-time injuries were reported during the period.

Bajaj Healthcare has received regulatory approval from the Drug Controller General of India (DCGI) under the Central Drugs Standard Control Organization (CDSCO) to manufacture and market Cenobamate API and tablets. The approval covers six strengths: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.

This regulatory clearance makes Bajaj Healthcare the first company in India to launch Cenobamate, a next-generation antiseizure medication indicated for treating partial-onset seizures in adults. The approval follows a recommendation from the Subject Expert Committee (SEC) for Neurology & Psychiatry, which the company previously communicated on June 26, 2026.

Strategic Significance

Cenobamate addresses a critical need in epilepsy care, with clinical studies demonstrating significant seizure reduction and high seizure-freedom rates in patients with inadequately controlled epilepsy. The launch strengthens Bajaj Healthcare’s presence in the Central Nervous System (CNS) segment.

Anil Jain, Managing Director of Bajaj Healthcare, stated that the approval reflects the company’s commitment to developing differentiated, complex, and high-value pharmaceutical products. He noted that the milestone demonstrates the strength of the company’s integrated API and formulation capabilities.

Product Portfolio Expansion

The company plans to take the product to market immediately, aiming to build Cenobamate as a key addition to its pharmaceutical portfolio. Management believes this launch will strengthen its CNS franchise and create opportunities for sustainable long-term growth.

Bajaj Healthcare operates state-of-the-art manufacturing facilities designed to meet requirements for both regulated and emerging markets. The company serves customers across Europe, the USA, Australia, the Middle East, and South America.